Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

(2017) Megan E. B. Clowse et al.   Arthritis & Rheumatology

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

(2017) Simon J. Bowman et al.   Arthritis & Rheumatology

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

(2016) D. J. Wallace et al.   ARTHRITIS CARE & RESEARCH

Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor

(2016) Simon Lumb et al.   Journal of Cell Communication and Signaling

Multiple Roles for B-Lymphocytes in Sjogren’s Syndrome

(2016) Julian Ambrus et al.   Journal of Clinical Medicine

Update on the immunobiology of Sjögrenʼs syndrome

(2015) Aurélie Ambrosi et al.   CURRENT OPINION IN RHEUMATOLOGY

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients

(2015) Vanessa Fleischer et al.   ARTHRITIS RESEARCH & THERAPY

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

(2013) Xavier Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia

(2013) D. Rossi et al.   BLOOD

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

The pathogenesis of systemic lupus erythematosus—an update

(2012) Jinyoung Choi et al.   CURRENT OPINION IN IMMUNOLOGY

The Role of Ectopic Germinal Centers in the Immunopathology of Primary Sjögren's Syndrome: A Systematic Review

(2012) Anna P. Risselada et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Significance of B cells and B cell clonality in Sjögren's syndrome

(2010) Pierre Youinou et al.   ARTHRITIS AND RHEUMATISM

Pathogenesis of Sjögrenʼs syndrome and therapeutic consequences

(2010) Xavier Mariette et al.   CURRENT OPINION IN RHEUMATOLOGY

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

(2009) Chee-Seng Yee et al.   RHEUMATOLOGY

Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

(2008) S Dass et al.   ANNALS OF THE RHEUMATIC DISEASES